Titre:
  • Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Auteur:Adès, Lionel; Boehrer, S; Prebet, Thomas; Beyne-Rauzy, Odile; Legros, Laurence; Ravoet, Christophe; Dreyfus, François; Stamatoullas, Aspasia; Chaury, Marie Pierre; Delaunay, Jacques; Laurent, Gauthier; Vey, Norbert; Burcheri, Sara; Mbida, Rose-Marie; Hoarau, Natacha; Gardin, C; Fenaux, Pierre
Informations sur la publication:Blood, 113, 17, page (3947-3952)
Statut de publication:Publié, 2009-04
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Aged, 80 and over
Chromosome Deletion
Chromosomes, Human -- genetics
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes -- drug therapy -- genetics -- pathology
Prognosis
Risk Factors
Survival Rate
Thalidomide -- adverse effects -- analogs & derivatives -- pharmacology -- therapeutic use
Treatment Outcome
Note générale:Clinical Trial, Phase II
Journal Article
Langue:Anglais
Identificateurs:urn:issn:0006-4971
info:doi/10.1182/blood-2008-08-175778
info:pii/blood-2008-08-175778
info:pmid/18987358